Stocks
Amgen Financial Statements (AMGN) |
||||||||||
| Amgensmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 09.02.2021 | 16.02.2022 | 31.12.2022 | 09.02.2023 | 14.02.2024 | 31.10.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 25 424 | 25 979 | 26 323 | 26 323 | 28 190 | 32 620 | |||
| Operating Income, bln rub | 5 794 | 6 005 | 9 566 | 5 335 | 7 897 | 6 750 | ||||
| EBITDA, bln rub | ? | 12 929 | 12 542 | 8 752 | 12 093 | 12 235 | 12 911 | |||
| Net profit, bln rub | ? | 7 264 | 5 893 | 6 552 | 6 552 | 6 717 | 4 209 | |||
| OCF, bln rub | ? | 10 497 | 9 261 | 9 721 | 9 721 | 8 471 | 9 178 | |||
| CAPEX, bln rub | ? | 608.0 | 880.0 | 936.0 | 936.0 | 1 112 | 963.0 | |||
| FCF, bln rub | ? | 9 889 | 8 381 | 8 785 | 8 785 | 7 359 | 8 215 | |||
| Dividend payout, bln rub | 3 755 | 4 013 | 0.000 | 4 196 | 4 556 | 3 627 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 51.7% | 68.1% | 0.00% | 64.0% | 67.8% | 86.2% | ||||
| OPEX, bln rub | 10 126 | 10 381 | 10 351 | 10 351 | 11 878 | 12 888 | ||||
| Cost of production, bln rub | 6 159 | 6 454 | 6 406 | 6 406 | 8 451 | 12 982 | ||||
| R&D, bln rub | 4 207 | 4 819 | 4 434 | 4 434 | 4 784 | 5 687 | ||||
| Interest expenses, bln rub | 1 262 | 1 197 | 1 406 | 1 406 | 2 875 | 3 216 | ||||
| Assets, bln rub | 62 948 | 61 165 | 65 121 | 65 121 | 97 154 | 90 883 | ||||
| Net Assets, bln rub | ? | 9 409 | 6 700 | 3 661 | 3 661 | 6 232 | 7 527 | |||
| Debt, bln rub | 32 986 | 33 309 | 38 945 | 38 945 | 64 613 | 60 398 | ||||
| Cash, bln rub | 10 647 | 8 037 | 9 305 | 9 305 | 10 944 | 9 011 | ||||
| Net debt, bln rub | 22 339 | 25 272 | 29 640 | 29 640 | 53 669 | 51 387 | ||||
| Ordinary share price, rub | 229.9 | 225.0 | 262.6 | 262.6 | 288.0 | 268.0 | ||||
| Number of ordinary shares, mln | 586.0 | 570.0 | 538.0 | 538.0 | 535.0 | 537.0 | ||||
| Market cap, bln rub | 134 733 | 128 233 | 141 300 | 141 300 | 154 091 | 143 927 | ||||
| EV, bln rub | ? | 157 072 | 153 505 | 170 940 | 170 940 | 207 760 | 195 314 | |||
| Book value, bln rub | -21 867 | -23 372 | -27 948 | -27 948 | -45 038 | -40 051 | ||||
| EPS, rub | ? | 12.4 | 10.3 | 12.2 | 12.2 | 12.6 | 7.84 | |||
| FCF/share, rub | 16.9 | 14.7 | 16.3 | 16.3 | 13.8 | 15.3 | ||||
| BV/share, rub | -37.3 | -41.0 | -51.9 | -51.9 | -84.2 | -74.6 | ||||
| EBITDA margin, % | ? | 50.9% | 48.3% | 33.2% | 45.9% | 43.4% | 39.6% | |||
| Net margin, % | ? | 28.6% | 22.7% | 24.9% | 24.9% | 23.8% | 12.9% | |||
| FCF yield, % | ? | 7.34% | 6.54% | 6.22% | 6.22% | 4.78% | 5.71% | |||
| ROE, % | ? | 77.2% | 88.0% | 179.0% | 179.0% | 107.8% | 55.9% | |||
| ROA, % | ? | 11.5% | 9.63% | 10.1% | 10.1% | 6.91% | 4.63% | |||
| P/E | ? | 18.5 | 21.8 | 21.6 | 21.6 | 22.9 | 34.2 | |||
| P/FCF | 13.6 | 15.3 | 16.1 | 16.1 | 20.9 | 17.5 | ||||
| P/S | ? | 5.30 | 4.94 | 5.37 | 5.37 | 5.47 | 4.41 | |||
| P/BV | ? | -6.16 | -5.49 | -5.06 | -5.06 | -3.42 | -3.59 | |||
| EV/EBITDA | ? | 12.1 | 12.2 | 19.5 | 14.1 | 17.0 | 15.1 | |||
| Debt/EBITDA | 1.73 | 2.01 | 3.39 | 2.45 | 4.39 | 3.98 | ||||
| R&D/CAPEX, % | 691.9% | 547.6% | 473.7% | 473.7% | 430.2% | 590.6% | ||||
| CAPEX/Revenue, % | 2.39% | 3.39% | 3.56% | 3.56% | 3.94% | 2.95% | ||||
| Amgen shareholders | ||||||||||
